tradingkey.logo
tradingkey.logo

Biomarin Pharmaceutical Inc - Discontinues Phase 2 Voxzogo Trials In Turner Syndrome, Shox-Deficiency, Acan-Deficiency - SEC Filing

ReutersMar 16, 2026 12:38 PM

- Biomarin Pharmaceutical Inc BMRN.O:

  • BIOMARIN PHARMACEUTICAL INC - DISCONTINUES PHASE 2 VOXZOGO TRIALS IN TURNER SYNDROME, SHOX-DEFICIENCY, ACAN-DEFICIENCY - SEC FILING

  • BIOMARIN: DECISION TO DISCONTINUE FOLLOWING OCCURRENCE OF SEVERAL SLIPPED CAPITAL FEMORAL EPIPHYSIS EVENTS IN 2 ONGOING INVESTIGATOR-SPONSORED TRIALS

  • BIOMARIN PHARMACEUTICAL - PHASE 2 CANOPY TRIALS OF VOXZOGO IN NOONAN SYNDROME, IDIOPATHIC SHORT STATURE TO CONTINUE - SEC FILING

Source text: []

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI